A Phase 1 First in Human, Single and Multiple Ascending Dose, Food Effect, and Drug-Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-CLS-616
Latest Information Update: 28 Nov 2024
Price :
$35 *
At a glance
- Drugs ABBV CLS 616 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors AbbVie
- 28 Nov 2024 New trial record